Search Results - nia

6 Results

Sort By:

Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis

Abstract: Over 32 million Americans are living with Diabetes and newly diagnosed cases of type 1 and type 2 diabetes is increasing. A defining feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide (IAPP) fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Mounting...

Published: 4/8/2024 | Inventor(s): Qing Rong Liu, Min Zhu, Pingbo Zhang, Josephine Egan, Luigi Ferrucci

Keywords(s): Alzheimer’s Disease, Amyloidosis, C-peptide, DIABETES, Egan, insulin, Islet Amyloid Polypeptide, Liu, National Institute on Aging, NIA

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Endocrinology

Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs

Abstract: Inflammatory processes associated with the over-production of tumor necrosis-alpha (TNF-alpha), a potent activator of the immune system accompany numerous neurodegenerative diseases. TNF-alpha has been validated as a drug target with the development of the inhibitors Enbrel and Remicade (fusion antibodies) as prescription medications. Both,...

Published: 4/8/2024 | Inventor(s): Nigel Greig, Weiming Luo, David Tweedie, Harold Holloway, Qian-sheng Yu, Edward Goetzl

Keywords(s): CNS, Holloway, Immunomodulatory Agents, Inflammation, Lenalidomide, National Institute on Aging, Neurodegenerative Disorders, NIA, THALIDOMIDE, TNF-alpha, Tumor Necrosis-alpha

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease

Abstract: There are no effective treatments for Alzheimer’s disease (AD), a progressive brain disease that slowly destroys a person’s memory, cognitive skills and ability to carry out the simplest tasks. AD affects more than 5 million individuals in the United States and ranks as the sixth leading cause of death. The ε4 allele of the apolipoprotein-E...

Published: 4/8/2024 | Inventor(s): Madhav Thambisetty

Keywords(s): Alzheimer’s Disease, ApoE, Apolipoprotein-E, Aβ, FYN, National Institute on Aging, Neuroinflammation, NIA, STAT3, Tau Phosphorylation, Thambisetty, YES1

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology, Collaboration Sought > Licensing

Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation

Abstract: Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer’s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-β is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to β-cell dysfunction....

Published: 5/23/2024 | Inventor(s): Qing Rong Liu, Min Zhu, Josephine Egan

Keywords(s): Ad, Age-Associated Disease, Alzheimer’s Disease, Amyloidosis, Amyloids, Biomarkers, DIABETES, IAPP, Islet Amyloid Polypeptide Isoforms, Liu, National Institute on Aging, NIA, PEPTIDYL

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Topoisomerase III (TOP3) Inhibitors and Antiviral Compounds based on Cyanine Dyes

Topoisomerase 3B (TOP3B) is the only topoisomerase that can act on RNA as well as DNA, and thus has been a target of interest for the development of cancer therapies and RNA viral infection therapies. In the context of cancer, TOP3B is not an essential gene, but a subset of cancer cells with pre-existing genome instability are particularly vulnerable...

Published: 4/8/2024 | Inventor(s): Yves Pommier, Shar-yin Huang, Wenjie Wang, Weidong Wang, Sourav Saha, Tianyi Zhang, Mariano Garcia-Blanco, Pei-Yong Shi, Yuk-Ching Tse-Dinh, Debbie Kennedy-Boone

Keywords(s): CANCER, Cyanine Dye, NIA, Pommier, SARS-CoV-2, TOP, TOP3, TOP3 Inhibitor, TOPOISOMERASE, Topoisomerase III, Topoisomerase Inhibitor, viral infection, Wang

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology

Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer

Abstract: A significant challenge in developing therapies for the treatment and prevention of cancer has been the discovery, selection, and exploitation of antigens. Researchers at the National Institute on Aging (NIA) have partially circumvented this issue in their development of novel strategies for rendering weakly or non-immunogenic, shared antigens...

Published: 4/8/2024 | Inventor(s): Bira Arya, Dan Longo, Igor Espinoza-Delgado

Keywords(s): ANTIGEN, Biragyn, CANCER VACCINE, Chemokine, National Institute on Aging, NIA

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics